[Rapport de recherche] Le CIN & La taille du marché du traitement HR-HPV devrait atteindre 17 164,61 millions de dollars US d’ici 2028, contre 11 635,17 millions de dollars US en 2022 ; on estime que le marché enregistrera un TCAC de 6,7 % de 2023 à 2028.
Le CIN & Le marché du traitement HR-HPV est segmenté en fonction du type de maladie, du type de souche, des offres, du type de produit, de l’utilisateur final et de la géographie. Le rapport offre des informations et une analyse approfondie du marché, mettant l’accent sur des paramètres tels que les moteurs, les tendances et les opportunités du marché et une analyse du paysage concurrentiel des principaux acteurs du marché dans diverses régions. Il comprend également des analyses de l'impact de la pandémie de COVID-19 dans les principales régions.
Aperçu du marché
Des initiatives favorables à la prévention du cancer du col de l'utérus stimulent les CIN et les autres tendances du marché. Croissance du marché du traitement HR-HPV
En août 2020, l'Organisation mondiale de la santé (OMS) a conçu une stratégie mondiale pour l'élimination du cancer du col de l'utérus. Selon cette stratégie, tous les pays du monde doivent s’efforcer d’atteindre et de maintenir un taux d’incidence inférieur à 4 pour 100 000 femmes afin d’éliminer le cancer du col de l’utérus. Pour atteindre des taux d'incidence aussi faibles, les pays devraient se concentrer sur le dépistage, le traitement et la vaccination du cancer du col de l'utérus. Medicare, un programme d'assurance gouvernemental populaire, couvre les tests PAP, les examens pelviens et les examens cliniques des seins effectués tous les deux ans pour le dépistage du cancer du col de l'utérus.
Unitaid, une agence mondiale de santé qui s'efforce de proposer des solutions innovantes. pour prévenir, diagnostiquer et traiter les principales maladies dans les pays à revenu faible ou intermédiaire, a mis au point une nouvelle initiative pour la prévention du cancer du col de l'utérus. Ses efforts visent à élargir l’accès aux outils et services essentiels pour dépister les premiers signes du cancer du col de l’utérus, suivis du traitement des cas positifs. Unitaid soutient la Clinton Health Access Initiative (CHAI) et le projet Scale Up Cervical Cancer Elimination with Secondaire Prevention Strategy (SUCCESS), menés en partenariat avec Expertise France, Jhpiego et l'Union internationale de lutte contre le cancer ( UICC). Unitaid collabore avec ces partenaires et les gouvernements de 14 pays à revenu faible ou intermédiaire pour développer un ensemble d'outils abordables et très efficaces, qui peuvent aider l'Organisation mondiale de la santé à atteindre ses objectifs d'élimination du cancer du col de l'utérus. Unitaid a investi environ 70 millions de dollars américains dans des outils innovants permettant de dépister les maladies précancéreuses des femmes vivant dans des environnements à faibles ressources et de les traiter. Dans 14 pays, Unitaid s'efforce de surmonter les obstacles à l'accès et de jeter les bases des efforts nationaux d'élimination du cancer du col de l'utérus, en démontrant des modèles de prévention efficaces dans les pays à revenu faible et intermédiaire.
Aperçus stratégiques
< p>En Inde, des méthodes de dépistage telles que la cytologie, les co-tests (HPV + cytologie), les tests primaires de HPV et l'inspection visuelle à l'acide acétique sont utilisées dans divers contextes, en fonction de la disponibilité des ressources et des normes de conformité. La Fédération des obstétriciens et gynécologues de l'Inde (FOGSI) a publié des recommandations de bonnes pratiques cliniques (GCPR) pour la prise en charge des femmes dépistées positives dans différents contextes de ressources. RMNCH + A (qui signifie Reproductive Maternal Neonatal Childhood Health + Adolescent Health + Adolescent) est la stratégie de la National Health Mission of India (NHM) qui encourage les normes familiales réduites. Cette stratégie consiste à fournir des contraceptifs à domicile par des militants accrédités en santé sociale (ASHA), à retarder l'âge du mariage, à promouvoir l'hygiène menstruelle et la sensibilisation à l'hygiène sexuelle, et à inciter au traitement des maladies de l'appareil reproducteur dans les « cliniques Suraksha ».De telles cliniques les initiatives de divers organismes de santé et gouvernements pour prévenir le cancer du col de l'utérus stimulent la croissance du CIN & Marché du traitement HR-HPV.
Informations basées sur le type de maladie
En fonction du type de maladie, les CIN & Le marché du traitement HR-HPV est segmenté en néoplasie intraépithéliale cervicale 1 (CIN 1), néoplasie intraépithéliale cervicale 2 (CIN 2) et néoplasie intraépithéliale cervicale 3 (CIN 3). En 2022, le segment de la néoplasie intraépithéliale cervicale 3 (CIN 3) détenait la plus grande part de marché et il devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
CIN & Marché du traitement HR-HPV, par type de maladie - 2022-2028
Informations basées sur le type de souche
En fonction du type de souche, les critères CIN etamp; Le marché du traitement HR-HPV est segmenté en HPV 16, HPV 18 et autres. Le segment HPV 16 détenait la plus grande part du marché en 2022. Le segment HPV 18 devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Informations basées sur l'offre
Basé sur offre, le CIN & Le marché du traitement HR-HPV est classé en méthode de diagnostic et en traitement. En 2022, le segment du traitement détenait une part de marché plus importante. Cependant, le segment des méthodes de diagnostic devrait enregistrer un TCAC plus élevé au cours de la période de prévision. En outre, le segment des méthodes de diagnostic est en outre classé en tests HPV, test Pap, colposcopie et biopsie. Le segment des tests HPV détenait la plus grande part du marché des méthodes de diagnostic en 2022. De plus, le segment du traitement est divisé en chirurgie excisionnelle et techniques ablatives. En 2022, le segment des techniques ablatives détenait une part de marché plus importante et devrait enregistrer un TCAC plus élevé sur le marché au cours de la période de prévision.
Informations basées sur le type de produit
Basé sur le type de produit, le CIN & Le marché du traitement HR-HPV est segmenté en kits et en kits. réactifs, instruments et services. Le segment des services détenait la plus grande part du marché en 2022 et devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Informations basées sur l'utilisateur final
Basées sur l'utilisateur final. , le CIN & Le marché du traitement HR-HPV est segmenté en hôpitaux et en hôpitaux. cliniques, laboratoires de diagnostic, laboratoires cliniques spécialisés et autres. L'hôpital & Le segment des cliniques représentait la plus grande part de marché en 2022. Le segment des laboratoires de diagnostic devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Le segment CIN & Les acteurs du marché du traitement HR-HPV adoptent des stratégies organiques telles que le lancement et l’expansion de produits pour élargir leur empreinte géographique et leurs portefeuilles de produits. De plus, ces stratégies de croissance aident les entreprises à renforcer leur clientèle et à élargir leur portefeuille de produits.
- En octobre 2022, Fujirebio Europe et Self-screen BV ont formé une collaboration commerciale. pour distribuer le test de diagnostic moléculaire in vitro (IVD) spécifique à la méthylation PreCursor-M+ (une marque déposée de Self-screen BV). Le test est destiné à détecter qualitativement les niveaux élevés de méthylation des biomarqueurs du cancer du col de l’utérus. Il peut être utilisé comme test de suivi de triage chez les femmes présentant des résultats positifs au VPH et une cytologie ASCUS/LSIL. Le test PreCursor-M+ complète le portefeuille de tests moléculaires spécifiques au VPH de Fujirebio.
- En avril 2021, Roche a reçu l'approbation de la FDA américaine pour les systèmes cobas 6800/8800 entièrement automatisés et à haut débit destinés à leur utilisation dans les tests VPH. Le test cobas HPV identifie les femmes à risque de cancer du col de l'utérus en détectant la présence d'ADN hrHPV dans des échantillons cervicaux. cobas HPV est indiqué pour le dépistage systématique du cancer du col de l'utérus conformément aux directives médicales professionnelles, y compris le triage de la cytologie ASC-US et le dépistage primaire du VPH chez les femmes afin d'évaluer le risque de précancer et de cancer du col de l'utérus.
Profils des sociétés
- Fujirebio Europe NV
- Qiagen NV
- Zilico Ltd
- Laboratoires Abbott
- Céphéides ;
- F. Hoffmann-La Roche SA
- INOVIO Pharmaceuticals Inc
- Bioneer Corp
- Antiva Biosciences Inc
- Thermo Fisher Scientific Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global CIN and HR-HPV Treatment Market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the CIN and HR-HPV Treatment Market in 2021. With several North American market players focusing on research and development activities, the regional market for CIN and HR-HPV Treatment Market is likely to propel in North America region during the forecast period.
Abbott and Cepheid are the top two companies that hold huge market shares in the CIN & HR-HPV Treatment Market.
The CIN and HR-HPV Treatment Market majorly consists of the players such Fujirebio Europe NV, Qiagen NV, Zilico Ltd, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd, INOVIO Pharmaceuticals Inc, Bioneer Corp, Antiva Biosciences Inc, and Thermo Fisher Scientific Inc.
The hospitals & clinics segment dominated the global CIN and HR-HPV Treatment Market and held the largest market share in 2021.
The CAGR value of the CIN and HR-HPV Treatment Market during the forecasted period of 2022-2028 is 6.7%.
Cervical Intraepithelial Neoplasia 3 segment held the largest share of the market in the global CIN and HR-HPV Treatment Market and held the largest market share of 47.48% in 2022.
High-risk HPV is associated with cervical intraepithelial neoplasia (CIN). Persistent infection with high-risk human papillomavirus (HPV) results in invasive cervical cancer. Also, HR-HPV subtypes particularly HPV 16 and HPV 18 causes cervical cancer. The main aim of NHS Cervical Screening Program (NHS CSP) is to reduce the incidence and mortality from cervical cancer through a systematic, quality-assured population-based screening program for people aged 24 to 64.
Key factors that are driving the growth of this market are Increase in prevalence of human papillomavirus infections and favorable Initiatives for preventing cervical cancer.
The List of Companies - CIN & HR-HPV Treatment Market
- Fujirebio Europe NV
- Qiagen NV
- Zilico Ltd
- Abbott Laboratories
- Cepheid
- F. Hoffmann-La Roche Ltd
- INOVIO Pharmaceuticals Inc
- Bioneer Corp
- Antiva Biosciences Inc
- Thermo Fisher Scientific Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
May 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
May 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
May 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
May 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
May 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)